| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SNSE | Common Stock | Purchase | $20.6K | +4.95K | +0.1% | $4.17 | 5.19M | Feb 17, 2022 | Direct | F1, F2 |
| transaction | SNSE | Common Stock | Purchase | $59.6K | +15K | +0.29% | $3.97 | 5.21M | Feb 18, 2022 | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares. |
| F2 | The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein. |
| F3 | The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.85 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein. |